Back to Search
Start Over
Prognostic Significance of β-Catenin in Relation to the Tumor Immune Microenvironment in Oral Cancer.
- Source :
- Biomedicines; Oct2023, Vol. 11 Issue 10, p2675, 14p
- Publication Year :
- 2023
-
Abstract
- The aim of this study was to investigate the prognostic relevance of β-catenin expression in oral squamous cell carcinoma (OSCC) and to explore relationships with the tumor immune microenvironment. Expression of β-catenin and PD-L1, as well as lymphocyte and macrophage densities, were evaluated by immunohistochemistry in 125 OSCC patient specimens. Membranous β-catenin expression was detected in 102 (81.6%) and nuclear β-catenin in 2 (1.6%) tumors. There was an association between β-catenin expression, tumoral, and stromal CD8<superscript>+</superscript> T-cell infiltration (TIL) and also the type of tumor immune microenvironment (TIME). Tumors harboring nuclear β-catenin were associated with a type II TIME (i.e., immune ignorance defined by a negative PD-L1 expression and low CD8<superscript>+</superscript> TIL density), whereas tumors with membranous β-catenin expression were predominantly type IV (i.e., immune tolerance defined by negative PD-L1 and high CD8<superscript>+</superscript> TIL density). Combined, but not individual, high stromal CD8<superscript>+</superscript> TILs and membranous β-catenin expression was independently associated with better disease-specific survival (HR = 0.48, p = 0.019). Taken together, a combination of high stromal CD8<superscript>+</superscript> T-cell infiltration and membranous β-catenin in the tumor emerges as an independent predictor of better survival in OSCC patients. [ABSTRACT FROM AUTHOR]
- Subjects :
- TUMOR microenvironment
ORAL cancer
SQUAMOUS cell carcinoma
IMMUNOLOGICAL tolerance
Subjects
Details
- Language :
- English
- ISSN :
- 22279059
- Volume :
- 11
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Biomedicines
- Publication Type :
- Academic Journal
- Accession number :
- 173264527
- Full Text :
- https://doi.org/10.3390/biomedicines11102675